Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calibration of solar pyranometers for accurate solar irradiance measurements: A data set from the pre- and post-calibration process.

Data in brief·2025
Same author

Assessing thermal performance: Dataset from an experimental study on U-value variability.

Data in brief·2024
Same author

[Suicide attempts with a violent method: Experience of a transdisciplinary psychiatric ward combining psychiatric and somatic care].

L'Encephale·2022
Same author

Intramyocardial transplantation of mesenchymal stromal cells for chronic myocardial ischemia and impaired left ventricular function: Results of the MESAMI 1 pilot trial.

International journal of cardiology·2016
Same author

Impact of pre-transplant diffusion lung capacity for nitric oxide (DLNO) and of DLNO/pre-transplant diffusion lung capacity for carbon monoxide (DLNO/DLCO) ratio on pulmonary outcomes in adults receiving allogeneic stem cell transplantation for hematological diseases.

Bone marrow transplantation·2015
Same author

Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT.

Bone marrow transplantation·2014

Related Experiment Video

Updated: Jun 23, 2026

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

[Cell therapy for acute myocardial infarction].

P Lemarchand1

  • 1Inserm, UMR915, Faculté de Médecine,Institut du Thorax, 44000 Nantes, France. patricia.lemarchand@univ-nantes.fr

Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine
|May 16, 2009
PubMed
Summary

Bone marrow stem cell therapy shows potential for repairing heart tissue after acute myocardial infarction (AMI). While early trials suggest safety and improved cardiac function, further large-scale studies are needed to confirm efficacy.

More Related Videos

Intramyocardial Cell Delivery: Observations in Murine Hearts
08:12

Intramyocardial Cell Delivery: Observations in Murine Hearts

Published on: January 24, 2014

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

Related Experiment Videos

Last Updated: Jun 23, 2026

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

Intramyocardial Cell Delivery: Observations in Murine Hearts
08:12

Intramyocardial Cell Delivery: Observations in Murine Hearts

Published on: January 24, 2014

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

Area of Science:

  • Cardiology
  • Regenerative Medicine
  • Stem Cell Biology

Context:

  • Acute myocardial infarction (AMI) significantly contributes to heart failure and mortality.
  • Limited natural regeneration capacity of injured cardiac tissue necessitates therapeutic interventions.
  • Bone marrow stem/progenitor cells are investigated for their potential to repair vascular and cardiac damage post-AMI.

Purpose:

  • To review the progress and outcomes of stem cell therapy for acute myocardial infarction (AMI).
  • To evaluate the safety and efficacy of bone marrow stem/progenitor cell administration following AMI.
  • To identify the need for further large-scale clinical trials to establish the therapeutic benefits of cardiac cell therapy.

Summary:

  • Initial Phase I clinical trials (2002-2004) indicated safety and promising improvements in clinical outcomes and cardiac function after AMI with stem cell therapy.
  • Recent randomized controlled trials have yielded mixed results.
  • A meta-analysis of 13 trials (811 participants) demonstrated a modest 2.99% improvement in left ventricular ejection fraction.

Impact:

  • Stem cell therapy represents a promising avenue for treating AMI, potentially reducing heart failure and mortality.
  • Current evidence suggests a need for larger, multicenter international trials to definitively establish the clinical efficacy of cardiac cell therapy.
  • Further research is crucial to optimize cell types, delivery methods, and patient selection for maximizing therapeutic benefits in AMI patients.